SSTR2 and Patent ductus arteriosus: This may explain the failure of sst2-selective somatostatin analogs such as octreotide to treat and detect PDA (octreoscan) in patients, since sst2 is not expressed in the two PDA major cell types, i.e. pancreatic cancer cells and CAFs [14, 19].